Nanoscience has long been lauded as a method through which tumor-associated barriers
could be overcome. As successful as cancer immunotherapy has been, limitations …

Immunostimulatory agonists such as anti-CD137 and interleukin (IL)-2 have elicited potent
antitumor immune responses in preclinical studies, but their clinical use is limited by …

Recent advances in the field of immunotherapy have profoundly opened up the potential for
improved cancer therapy and reduced side effects. However, the tumor microenvironment …

Immune checkpoint blockade treatment is one of the most promising immunotherapies,
which exhibits promising therapeutic effects on inhibition of metastasis. However …

Tumor immunotherapy, especially immune checkpoint blockade (ICB), has revolutionized
the cancer field. However, the limited response of tumors to immunotherapy is a major …

Liposomes are clinically used as drug carriers for cancer therapy; however, unwanted
leakage of the encapsulated anticancer drug and poor tumor-targeting efficiency of …

Despite immunotherapy having revolutionized cancer therapy, the efficacy of
immunotherapy in triple-negative breast cancer (TNBC) is seriously restricted due to the …

Impaired type I interferons (IFNs) may cause immune deficiency in tumours. Current
supplementary IFN therapy partially restores anticancer immunity but simultaneously …

Cancer immunotherapy has revolutionized the standard of care for solid tumors in multiple
disease sites. In light of this, immune checkpoint blockade, directly interfering with various …

The clinical outcomes of cancer nanovaccine have been largely impeded owing to the low
antigen-specific T cell response rate and acquired resistance caused by the …